SAGE's Cookie Policy
Close 

To enhance your experience on our site, SAGE stores cookies on your computer. By continuing you consent to receive cookies.

Learn More

Therapeutic Advances in Endocrinology and Metabolism

Editor-in-Chief:
Hannover Medical School, Hannover, Germany
EDITOR:
SAGE Publications, UK
Associate Editors:
Hannover Medical School, Germany
Robert Hague Centre for Diabetes and Endocrinology, Barnsley Hospital NHS Foundation Trust, Barnsley, UK and Hormone and Vascular Biology Research Group, Academic Unit of Diabetes, Endocrinology & Metabolism, University of Sheffield Medical Sc
JCU School of Medicine and Dentistry, Australia
Novartis Pharma GmbH, Nuremberg, Germany
 

Therapeutic Advances in Endocrinology and Metabolism delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of endocrinology and metabolism. You can access the journal online for free at www.sagepub.com/tae.

The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in endocrinology and metabolism, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of endocrinology and metabolism, including obesity; diabetes mellitus; hypothalamic and pituitary disorders; posterior pituitary and electrolyte disorders; short and tall stature including growth hormone deficiency and treatment; metabolic bone disease; adrenal disorders; hyperlipidemia; endocrine hypertension; endocrine tumours; endocrine autoimmune states; thyroid disorders; thyroid tumours; male and female hypogonadism; reproductive endocrinology; paediatric endocrinology; geriatric endocrinology; and endocrine emergencies.

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed that show drug or drug class efficacy in a particular disease or therapeutic area. The journal strongly encourages the submission of original research with positive or negative results.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:
Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email. reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE).

Subscription Information :
Institutional Subscription, Combined (Print & E-access) $1,181.00
Institutional Subscription, E-access $1,063.00
Institutional Subscription, Print Only $1,157.00
Individual Subscription, Print Only $152.00

Individual articles are available for immediate purchase online (See View Full-Text icon above). Print copies of individual issues can be purchased by contacting the SAGE Journals Customer Service department journals@sagepub.com 1-800-818-7243.

If you are eligible for non-standard pricing please contact Journals Customer Service department journals@sagepub.com 1-800-818-7243 for a price quote.

Institutional, Single Print Issue $212.00
Individual Single Print Issue $33.00
Frequency: Bi-monthly eISSN: 2042-0196 ISSN: 2042-0188
Months of Distribution: February , April , June , August , October , December Current Volume: 4 Current Issue: 6
Other Titles In:
-
-
-

Product Type

All

Subject Areas

All